We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Elemental is an agricultural food technology company that converts 78% of beef processing waste into sustainable fertiliser. The company claims that its technology can potentially reduce global beef CO2 emissions equivalent to 50 million cattle. Elemental asserts that its technology has been developed through extensive R&D and protected by patents in 60+ countries. The company raised £1.5 million on Crowdcube in late 2019, signed agreements for 14 projects in the UK and Europe using its technology, built a demonstrator plant and agreed to install its technology on commercial terms at 6 UK abattoirs. The company states they will use the investment to operationalise their first plant by December 2021 and grow their business across different verticals.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,395,801
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their helath where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go: Expired investment: £737,480
Sonichem responds to climate and environmental demands by developing sustainable chemicals, excluding those derived from fossils or crops used for food. They utilize sawmill waste, transforming the typically discarded woodchips and sawdust into sugars, cellulose, and lignin, essential bio-based chemicals, through their patented and scalable eco-friendly process. Achieving an impressive ratio, they turn £1 of sawdust into nearly £8 worth of these sustainable chemicals. Positioned within the rapidly growing $17 billion bio-based chemicals market, their innovation addresses the rising need for sustainable alternatives in plastics, cosmetics, and various industries, positioning Sonichem at the forefront of the eco-friendly revolution.
days to go: Expired investment: £1,232,585
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Toraphene is an environmental technology company that aims to eliminate plastic waste. It has released with its product, Toraphene, to solve this crisis. It claims that Toraphene is a biodegradable, compostable and commercially-viable plastic packaging substitute for conventional plastic. The company asserts that its product is biodegradable even in the ocean, and has been developed using graphene technology. It is focussed on eliminating carrier bags and food containers in its first-round which account for 23% of marine waste. It aims to be a segment leader in the projected $25.4 billion biodegradable plastic industry by 2026. The company will use the investment to make Toraphene accessible to companies worldwide and make plastic packaging obsolete.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £1,000,000
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Solaris Photonics Ltd are developing the next generation of clean energy systems, multiplying the output of solar panels. The Solaris Photonics Multiplier is a power electronics device which can be retrofitted to solar panels to increase their power output by up to 4 times. The Alkaline Photovoltaic is a versatile photovoltaic cell, which can transform any surface into a solar panel.
days to go: Expired investment: £585,000
Ripple is a platform that facilitates co-ownership of renewable energy sources like wind farms and solar parks for both households and businesses. Their goal is to transform the energy industry by allowing consumers to easily and affordably co-own these assets, providing direct benefits in terms of cost savings and convenience.
days to go: Expired investment: £1,683,160
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
days to go: Expired investment: £99,000
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph